On the Edge of My Seat

There's good news for us, breast cancer sufferers, walking around with sore tushies from monthly Fulvestrant shots. According to a recent press release, the Menarini Group and Radius Health announced positive phase three results for elacestrant, first oral SERD with positive topline results in pivotal study as monotherapy for the treatment of ER+/HER2- advanced or mBC.¹

Study finding for HER2- MBC

The two groups will present the findings of their study titled "the Emerald trial" at the 2021 San Antonio Breast Cancer Symposium (SABCS) in December, marking the first successful go at an oral SERD. In the past, patients had only one drug to choose from: Fulvestrant delivered through two large injections, 250mg injected slowly in each buttock, leaving mounds of uncomfortable pharmaceuticals resting in one's derriere. Hot pads and deep tissue massage were the only respites, not quite kosher for a working girl.¹

The trial tested 466 women in an open-labeled, randomized, active-controlled study evaluating elacestrant as second-or third-line therapy in ER+/HER2- ABC patients.¹

Having an oral option that we can take at home should prove useful to most post-menopausal women with estrogen-positive cancer or women with an ESR1 mutation. Thus, giving us all another option in our treatment regimens.

I know I will be sitting on the edge of my seat during the San Antonio Breast Cancer Symposium in December 2021, possibly because the fresh Fulvestrant made my booty hurt. But most likely because I will be excited to hear about this emerging possibility.

Will you be attending SABCS this year?

Editor's Note: We are extremely saddened to say that on September 6, 2023, Vicki Thompson passed away. Vicki's advocacy efforts and writing continue to reach many. She will be deeply missed.